Want to see HK:2186 full AI Analyst Report?
Luye Pharma Group (2186) Financial Statements
Luye Pharma Group Financial Overview
Luye Pharma Group's market cap is currently $6.23B. The company's EPS TTM is $0.17; its P/E ratio is 7.73; and it has a dividend yield of 2.66%. Luye Pharma Group is estimated to report earnings on March 31, 2027, and the estimated EPS forecast is $0.07. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 6.31B | $ 6.06B | $ 6.14B | $ 5.98B | $ 5.20B |
| Gross Profit | $ 4.16B | $ 4.04B | $ 4.20B | $ 4.14B | $ 3.40B |
| Operating Income | $ 1.24B | $ 1.15B | $ 917.88M | $ 880.62M | $ 437.96M |
| EBITDA | $ 2.06B | $ 1.92B | $ 2.08B | $ 1.81B | $ 906.88M |
| Net Income | $ 618.75M | $ 471.89M | $ 532.61M | $ 604.81M | $ -134.39M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 8.88B | $ 6.50B | $ 6.11B | $ 5.54B | $ 5.51B |
| Total Assets | $ 32.84B | $ 29.61B | $ 25.49B | $ 24.25B | $ 22.58B |
| Total Debt | $ 9.42B | $ 10.32B | $ 8.42B | $ 9.10B | $ 9.49B |
| Net Debt | $ 4.92B | $ 5.38B | $ 5.18B | $ 6.78B | $ 7.05B |
| Total Liabilities | $ 14.19B | $ 13.86B | $ 11.96B | $ 13.21B | $ 13.47B |
| Stockholders' Equity | $ 16.08B | $ 14.15B | $ 12.53B | $ 10.18B | $ 8.49B |
| Cash Flow | |||||
| Free Cash Flow | $ 780.44M | $ -1.54B | $ 430.23M | $ 490.14M | $ -1.36B |
| Operating Cash Flow | $ 1.78B | $ 167.76M | $ 1.60B | $ 1.65B | $ 182.37M |
| Investing Cash Flow | $ -3.99B | $ -1.47B | $ -1.42B | $ -1.66B | $ -3.44B |
| Financing Cash Flow | $ 1.79B | $ 2.96B | $ 841.60M | $ 54.15M | $ 1.88B |
Currency in CNY